SCHEMBL4028786

SCHEMBL4028786

Cc1cccc(C2C(C(=O)c3ccccc3)CN(CC(=O)NCCO)CC2C(=O)c2ccccc2)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
FGFR3 P22607 1/20 0.35
KDR P35968 1/20 0.35
DRD4 P21917 1/20 0.35
PLA2G1B P04054 1/20 0.34
NPY1R P25929 1/20 0.34
HTT P42858 1/20 0.34
NPY2R P49146 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028782 1.00 MEN1 (0.40) MEN1KMT2AMAPTGAALMNA
SCHEMBL4028149 0.87 MEN1 (0.38) MEN1KMT2AMAPTGAALMNA
SCHEMBL4028188 0.87 MEN1 (0.38) MEN1KMT2AMAPTGAALMNA
SCHEMBL4028145 0.87 MEN1 (0.38) MEN1KMT2AMAPTGAALMNA
SCHEMBL4026132 0.86 MEN1 (0.45) MEN1KMT2AMAPTGAATSHR
SCHEMBL4026128 0.86 MEN1 (0.45) MEN1KMT2AMAPTGAATSHR
SCHEMBL4024726 0.85 MAPT (0.47) MEN1KMT2AMAPTGAALMNA
SCHEMBL4024732 0.85 MAPT (0.47) MEN1KMT2AMAPTGAALMNA
SCHEMBL4021213 0.85 GRIN2B (0.38) MEN1KMT2AMAPTLMNAHTT
SCHEMBL4021208 0.85 GRIN2B (0.38) MEN1KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 MEN1 77/4885KMT2A 2820/4885MAPT 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.